IPCA Laboratories Share Price

Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.As of 15 Jun 2026, IPCA Laboratories share price is ₹1,583.00. The stock opened at ₹1,629.80, compared to its previous close of ₹1,613.60. During today's trading session, IPCA Laboratories share price moved in the range of ₹1,568.60 to ₹1,640.00, with an average price of ₹1,604.30 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,568.60 and a high of ₹1,640.00. On the performance front, IPCA Laboratories share price has increased by 7.99% over the last six months and is up 14.46% on a year-on-year basis.

The market capitalization of IPCA Laboratories is ₹40,232 Crs, with a P/E ratio of 34.0 and a dividend yield of 0.38%.